SCHEMBL4702192

SCHEMBL4702192

COc1ccc(COC(=O)C(CC(C)C)N(C(=O)OCC(Cl)(Cl)Cl)c2nn(C)cc2Br)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.36
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KMT2A Q03164 3/20 0.32
ALDH1A1 P00352 3/20 0.32
MEN1 O00255 1/20 0.32
PTGS2 P35354 1/20 0.32
CASP3 P42574 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MMP9 P14780 2/20 0.32
MMP2 P08253 1/20 0.32
MMP12 P39900 1/20 0.32
ATM Q13315 1/20 0.31
MAPT P10636 1/20 0.31
ANPEP P15144 1/20 0.31
CTSL P07711 1/20 0.31
CTSS P25774 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4702194 1.00 HTR2A (0.36) HTR2AGAASMN1; SMN2KMT2AALDH1A1
SCHEMBL4701883 0.87 ALDH1A1 (0.33) KMT2AALDH1A1ATM
SCHEMBL4701882 0.87 ALDH1A1 (0.33) KMT2AALDH1A1ATM
SCHEMBL4704675 0.73 NPC1 (0.34) HTR2ASMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL4704196 0.71 HTR2A (0.44) HTR2ASMN1; SMN2KMT2AALDH1A1PTGS2
SCHEMBL4704198 0.71 HTR2A (0.44) HTR2ASMN1; SMN2KMT2AALDH1A1PTGS2
SCHEMBL4704280 0.64 NPSR1 (0.35) ATM
SCHEMBL4704277 0.64 NPSR1 (0.35) ATM
SCHEMBL4701447 0.64 NPSR1 (0.32)
SCHEMBL4701381 0.62 ATM (0.49) SMN1; SMN2ALDH1A1MMP9MMP2MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1372655-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA LTD (CA) 2008-10-01 EP disclosed
US-7012075-B2 Cathepsin cysteine protease inhibitors MERCK & CO., INC. (US) 2006-03-14 US disclosed
EP-1372655-A4 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2005-10-12 EP disclosed
US-20040198982-A1 Cathepsin cysteine protease inhibitors MERCK CANADA INC. (CA) 2004-10-07 US disclosed
EP-1372655-A2 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Frosst Canada & Co. (CA) 2004-01-02 EP disclosed
WO-2002069901-A2 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA & CO. (CA) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198982-A1 Cathepsin cysteine protease inhibitors CTSB, CTSS, CTSZ HTR2A 4760/4885GAA 154/4885SMN1; SMN2 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.